Medical and Pharmaceutical FDA clears Median Technologies lung-nodule risk assessment software The Median system reported 93.3 per cent sensitivity and 92.4 per cent specificity when identifying malignant lung nodules Joseph MortonMarch 16, 2026
Medical and Pharmaceutical Tempus AI builds on FDA win with Median partnership for lung cancer detection Median secured FDA 510(k) approval for eyonis LCS on Feb. 9 Rowan DunneFebruary 23, 2026
Medical and Pharmaceutical Median Technologies clears hurdle on the way to regulatory acceptance in EU and US The company has met a key requirement for regulatory submissions in the US and Europe Joseph MortonApril 3, 2025
AI and Autonomy Median Technologies and European Investment Bank agrees to €37.5M loan The tech leverages machine learning to analyze imaging data generated by low-dose computed tomography Joseph MortonJanuary 28, 2025